pubmed-article:15162468 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:15162468 | lifeskim:mentions | umls-concept:C0023911 | lld:lifeskim |
pubmed-article:15162468 | lifeskim:mentions | umls-concept:C1882726 | lld:lifeskim |
pubmed-article:15162468 | lifeskim:mentions | umls-concept:C0021080 | lld:lifeskim |
pubmed-article:15162468 | lifeskim:mentions | umls-concept:C0003241 | lld:lifeskim |
pubmed-article:15162468 | lifeskim:mentions | umls-concept:C0085149 | lld:lifeskim |
pubmed-article:15162468 | lifeskim:mentions | umls-concept:C0021079 | lld:lifeskim |
pubmed-article:15162468 | lifeskim:mentions | umls-concept:C0750502 | lld:lifeskim |
pubmed-article:15162468 | lifeskim:mentions | umls-concept:C2349975 | lld:lifeskim |
pubmed-article:15162468 | lifeskim:mentions | umls-concept:C1627358 | lld:lifeskim |
pubmed-article:15162468 | pubmed:issue | 6 | lld:pubmed |
pubmed-article:15162468 | pubmed:dateCreated | 2004-5-26 | lld:pubmed |
pubmed-article:15162468 | pubmed:abstractText | A member of the costimulatory molecule family, inducible costimulator (ICOS), is expressed on activated T cells and plays a critical role in their primary activation and cytokine production. ICOS is involved in different immune phenomena, such as Th1-mediated autoimmune disease and graft rejection. Although blockade of ICOS costimulation theoretically may protect grafts from rejection, a single dose of anti-ICOS antibody did not result in the prolongation of rat liver allograft survival. However, in this article, we report that anti-rat ICOS antibody markedly enhanced the immunosuppressive activity of a suboptimal dose of tacrolimus (FK506). After fully allogenic DA to LEW liver transplantation, recipients received a single injection of tacrolimus (1 mg/kg, intramuscularly) with or without anti-ICOS antibody (1 mg/kg, intravenously). Recipient survival was significantly prolonged in rats treated with both the antibody and suboptimal tacrolimus (median survival time 44 days vs. 28 days with tacrolimus alone, P <.01). The extent of cell infiltration into the graft was closely associated with prolongation of recipient survival. Our findings thus demonstrate that anti-ICOS antibody immunotherapy combined with suboptimal tacrolimus has a synergistic effect in preventing hepatic allograft rejection and that it may induce long-term graft acceptance intimately associated with a marked reduction of intragraft T lymphocyte infiltration. | lld:pubmed |
pubmed-article:15162468 | pubmed:language | eng | lld:pubmed |
pubmed-article:15162468 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15162468 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:15162468 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15162468 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15162468 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15162468 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15162468 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15162468 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15162468 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15162468 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:15162468 | pubmed:month | Jun | lld:pubmed |
pubmed-article:15162468 | pubmed:issn | 1527-6465 | lld:pubmed |
pubmed-article:15162468 | pubmed:author | pubmed-author:DaiS JSJ | lld:pubmed |
pubmed-article:15162468 | pubmed:author | pubmed-author:SugawaraYasuh... | lld:pubmed |
pubmed-article:15162468 | pubmed:author | pubmed-author:MakuuchiMasat... | lld:pubmed |
pubmed-article:15162468 | pubmed:author | pubmed-author:LiXiao-KangXK | lld:pubmed |
pubmed-article:15162468 | pubmed:author | pubmed-author:FuneshimaNaok... | lld:pubmed |
pubmed-article:15162468 | pubmed:author | pubmed-author:SuzukiSeiichi... | lld:pubmed |
pubmed-article:15162468 | pubmed:author | pubmed-author:KimuraHiromit... | lld:pubmed |
pubmed-article:15162468 | pubmed:author | pubmed-author:EnosawaShinS | lld:pubmed |
pubmed-article:15162468 | pubmed:author | pubmed-author:TezukaKatsuna... | lld:pubmed |
pubmed-article:15162468 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:15162468 | pubmed:volume | 10 | lld:pubmed |
pubmed-article:15162468 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:15162468 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:15162468 | pubmed:pagination | 743-7 | lld:pubmed |
pubmed-article:15162468 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
pubmed-article:15162468 | pubmed:meshHeading | pubmed-meshheading:15162468... | lld:pubmed |
pubmed-article:15162468 | pubmed:meshHeading | pubmed-meshheading:15162468... | lld:pubmed |
pubmed-article:15162468 | pubmed:meshHeading | pubmed-meshheading:15162468... | lld:pubmed |
pubmed-article:15162468 | pubmed:meshHeading | pubmed-meshheading:15162468... | lld:pubmed |
pubmed-article:15162468 | pubmed:meshHeading | pubmed-meshheading:15162468... | lld:pubmed |
pubmed-article:15162468 | pubmed:meshHeading | pubmed-meshheading:15162468... | lld:pubmed |
pubmed-article:15162468 | pubmed:meshHeading | pubmed-meshheading:15162468... | lld:pubmed |
pubmed-article:15162468 | pubmed:meshHeading | pubmed-meshheading:15162468... | lld:pubmed |
pubmed-article:15162468 | pubmed:meshHeading | pubmed-meshheading:15162468... | lld:pubmed |
pubmed-article:15162468 | pubmed:meshHeading | pubmed-meshheading:15162468... | lld:pubmed |
pubmed-article:15162468 | pubmed:meshHeading | pubmed-meshheading:15162468... | lld:pubmed |
pubmed-article:15162468 | pubmed:meshHeading | pubmed-meshheading:15162468... | lld:pubmed |
pubmed-article:15162468 | pubmed:meshHeading | pubmed-meshheading:15162468... | lld:pubmed |
pubmed-article:15162468 | pubmed:meshHeading | pubmed-meshheading:15162468... | lld:pubmed |
pubmed-article:15162468 | pubmed:meshHeading | pubmed-meshheading:15162468... | lld:pubmed |
pubmed-article:15162468 | pubmed:meshHeading | pubmed-meshheading:15162468... | lld:pubmed |
pubmed-article:15162468 | pubmed:meshHeading | pubmed-meshheading:15162468... | lld:pubmed |
pubmed-article:15162468 | pubmed:meshHeading | pubmed-meshheading:15162468... | lld:pubmed |
pubmed-article:15162468 | pubmed:meshHeading | pubmed-meshheading:15162468... | lld:pubmed |
pubmed-article:15162468 | pubmed:meshHeading | pubmed-meshheading:15162468... | lld:pubmed |
pubmed-article:15162468 | pubmed:meshHeading | pubmed-meshheading:15162468... | lld:pubmed |
pubmed-article:15162468 | pubmed:meshHeading | pubmed-meshheading:15162468... | lld:pubmed |
pubmed-article:15162468 | pubmed:year | 2004 | lld:pubmed |
pubmed-article:15162468 | pubmed:articleTitle | Significant enhancement by anti-ICOS antibody of suboptimal tacrolimus immunosuppression in rat liver transplantation. | lld:pubmed |
pubmed-article:15162468 | pubmed:affiliation | Department of Innovative Surgery, National Research Institute for Child Health and Development, Tokyo, Japan. | lld:pubmed |
pubmed-article:15162468 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:15162468 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |